drugset
drugset / Trial / NCT05794204

RMP-A03 Ocular Suspension in Patients With Pterygium

NCT05794204 ↗

Phase 2 Completed 77 enrolled Suzhou Raymon Pharmaceuticals Company, Ltd. WuXi Clinical · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.

Timeline

Start
2023-06-09
Primary completion
2024-01-12
Completion
2024-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject RMP-A03 Unknown — —

Indications

pterygium